Rosemary (Rosmarinus officinalis L.) extract inhibits prostate cancer cell proliferation and survival by targeting Akt and mTOR - 28/10/20
pages | 12 |
Iconographies | 11 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Rosemary extract (RE) reduced proliferation and survival of prostate cancer cells. |
• | Normal epithelial cells remained unaffected by RE treatment. |
• | RE inhibited cell migration and enhanced cleaved PARP, an indicator of apoptosis. |
• | Prostate cancer cell Akt and mTOR phosphorylation/activation was inhibited by RE. |
Abstract |
Prostate cancer is the most commonly diagnosed type of cancer in North American men and is typically classified as either androgen receptor positive or negative depending on the expression of the androgen receptor (AR). AR positive prostate cancer can be treated with hormone therapy while AR negative prostate cancer is aggressive and does not respond to hormone therapy. It has been previously reported that rosemary extract (RE) has antioxidant, anti-inflammatory and anti-cancer properties. In the present study, we found that treatment of the androgen-insensitive PC-3 prostate cancer cells with RE resulted in a significant inhibition of proliferation, survival, migration, Akt, and mTOR signaling. In addition, treatment of the androgen-sensitive 22RV1 prostate cancer cells with RE resulted in a significant inhibition of proliferation and survival while RE had no effect on normal prostate epithelial PNT1A cells. These findings suggest that RE has potent effects against prostate cancer and warrants further investigation.
Le texte complet de cet article est disponible en PDF.Keywords : Rosemary extract, Prostate cancer, Proliferation, Survival, Akt, mTOR
Plan
Vol 131
Article 110717- novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?